价格

Liquidia Technologies, Inc.

ACTIVE

419 Davis Dr Ste 100, 北卡罗来纳州达勒姆县, 北卡罗来纳州, 美国www.liquidia.comPublic101–250 名员工成立于: 2004-01-017亿美元

别名:

liquidia technologies

隶属于 liquidia corp.

概览

试验阶段分布

阶段

试验数

占比

3 期

40.0%

1 期

20.0%

2 期

20.0%

4 期

10.0%

试验状态分布

进行中（未招募）

20.0%

已完成

30.0%

尚未招募

20.0%

招募中

20.0%

终止

10.0%

药物批准

按机构分类的批准

FDA

Food and Drug Administration

药物批准

近期批准

资讯

Pipeline for Pulmonary Arterial Hypertension Treatment Expands with 55+ Companies Developing Novel Therapies

- DelveInsight's latest report reveals over 55 companies actively developing 55+ pipeline drugs for Pulmonary Arterial Hypertension treatment, indicating robust research activity in this therapeutic area. - Breakthrough therapies like Sotatercept by Acceleron Pharma and LIQ861 by Liquidia Technologies are advancing through clinical trials, offering new hope for PAH patients. - Multiple clinical trials are underway in early 2025, including studies by Actelion, Keros Therapeutics, Insmed Incorporated, and Merck Sharp & Dohme, focusing on novel treatment approaches.

Feb 13, 2025

返回机构列表

Liquidia Technologies, Inc.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（10）

A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

药物批准

按机构分类的批准

近期批准

资讯

Pipeline for Pulmonary Arterial Hypertension Treatment Expands with 55+ Companies Developing Novel Therapies